Distribution of first biologic DMARDs in RA patients according to 5-years periods
| 2001-2005 | 2006-2010 | 2011-2015 | 2016-2020 | Total | |
| Adalimumab | 15 (23.1) | 111 (33.0) | 187 (21.8) | 153 (18.6) | 466 (22.4) |
| Etanercept | 30 (46.2) | 154 (45.8) | 229 (26.7) | 54 (6.6) | 467 (22.4) |
| İnfliximab | 20 (30.8) | 58 (17.3) | 64 (7.5) | 7 (0.9) | 149 (7.1) |
| Golimumab | 0 | 0 | 37 (4.3) | 43 (5.2) | 80 (3.8) |
| Certolizumab | 0 | 0 | 37 (4.3) | 68 (8.3) | 105 (5.0) |
| Anti-TNF | 65 (100) | 323 (96.4) | 554 (64.5) | 325 (39.5) | 1267 (60.9) |
| Tofacitinib | 0 | 0 | 6 (0.7) | 212 (25.8) | 218 (10.5) |
| Tocilizumab | 0 | 0 | 9 (1.0) | 102 (12.4) | 111 (5.3) |
| Rituximab | 0 | 12 (3.6) | 136 (15.8) | 84 (10.2) | 232 (11.1) |
| Abatacept | 0 | 0 | 153 (17.8) | 99 (12.0) | 252 (12.1) |
| Non-Anti-TNF | 0 | 12 (3.6) | 304 (35.5) | 497 (60.5) | 813 (39.1) |
| Total | 65 (100) | 335 (100) | 858 (100) | 822 (100) | 2080 (100) |
Approval years of drugs in Turkey; Infliximab: 2003, etanercept:2004, adalimumab: 2005, golimumab: 2013, certolizumab: 2014, abatacept: 2010, tocilizumab: 2013, rituximab:2009, tofacitinib: 2015,